[Successful delivery using interferon α for molecular relapse of chronic myeloid leukemia after interruption of tyrosine kinase inhibitor].

[Rinsho ketsueki] The Japanese journal of clinical hematology Pub Date : 2023-01-01 DOI:10.11406/rinketsu.64.102

Aya Shodai, Yukiko Tazaki, Natsuko Uchida, Tomonori Hamada, Rika Akahoshi, Takuya Ueno, Tomohisa Tabuchi, Naosuke Arima, Maiko Hayashida, Akihiko Arai, Daisuke Nakamura, Makoto Yoshimitsu, Hiroaki Kobayashi, Kenji Ishitsuka

{"title":"[Successful delivery using interferon α for molecular relapse of chronic myeloid leukemia after interruption of tyrosine kinase inhibitor].","authors":"Aya Shodai, Yukiko Tazaki, Natsuko Uchida, Tomonori Hamada, Rika Akahoshi, Takuya Ueno, Tomohisa Tabuchi, Naosuke Arima, Maiko Hayashida, Akihiko Arai, Daisuke Nakamura, Makoto Yoshimitsu, Hiroaki Kobayashi, Kenji Ishitsuka","doi":"10.11406/rinketsu.64.102","DOIUrl":null,"url":null,"abstract":"<p><p>A tyrosine kinase inhibitor (TKI) was used to treat the patient, a 35-year-old woman who was diagnosed with chronic myeloid leukemia at the age of 22 years. Since a four-year deep molecular response (DMR) was obtained, spontaneous pregnancy was planned under TKI withdrawal. Even though her disease had advanced to MR2.0 at the time of pregnancy confirmation, 2 months from TKI cessation, interferon α therapy was initiated in light of the patient's history. Later, the patient reached MR3.0, gave birth to a healthy baby, and maintained MR3.0-4.0. TKI was resumed after about 6 months of breastfeeding. Treatment-free remission (TFR) is required for natural conception despite the teratogenicity and miscarriage risks associated with BCR::ABL1 TKIs. When planning a pregnancy, it is also necessary to take the patients' backgrounds, disease states, and medical history into account.</p>","PeriodicalId":6352,"journal":{"name":"[Rinsho ketsueki] The Japanese journal of clinical hematology","volume":"64 2","pages":"102-106"},"PeriodicalIF":0.0000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"[Rinsho ketsueki] The Japanese journal of clinical hematology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.11406/rinketsu.64.102","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

A tyrosine kinase inhibitor (TKI) was used to treat the patient, a 35-year-old woman who was diagnosed with chronic myeloid leukemia at the age of 22 years. Since a four-year deep molecular response (DMR) was obtained, spontaneous pregnancy was planned under TKI withdrawal. Even though her disease had advanced to MR2.0 at the time of pregnancy confirmation, 2 months from TKI cessation, interferon α therapy was initiated in light of the patient's history. Later, the patient reached MR3.0, gave birth to a healthy baby, and maintained MR3.0-4.0. TKI was resumed after about 6 months of breastfeeding. Treatment-free remission (TFR) is required for natural conception despite the teratogenicity and miscarriage risks associated with BCR::ABL1 TKIs. When planning a pregnancy, it is also necessary to take the patients' backgrounds, disease states, and medical history into account.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

[使用干扰素 α 成功治疗中断酪氨酸激酶抑制剂后分子复发的慢性髓性白血病]。

患者是一名 35 岁女性，22 岁时被诊断出患有慢性髓性白血病，当时使用的是酪氨酸激酶抑制剂（TKI）。由于获得了四年的深度分子反应（DMR），她计划在停用 TKI 后自然怀孕。尽管在确认怀孕时她的病情已发展到 MR2.0，但在停止 TKI 治疗 2 个月后，还是根据患者的病史开始了干扰素 α 治疗。后来，患者的 MR 达到了 3.0，生下了一个健康的婴儿，并将 MR 维持在 3.0-4.0。哺乳约 6 个月后，TKI 恢复治疗。尽管 BCR::ABL1 TKIs 有致畸和流产风险，但自然受孕需要无治疗缓解（TFR）。在计划怀孕时，还需要考虑患者的背景、疾病状态和病史。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

[Rinsho ketsueki] The Japanese journal of clinical hematology

自引率

0.00%

发文量